GW’s cannabis-derived Epidiolex is a blockbuster drug in the making

cannabidiol
GW Pharmaceuticals has announced plans to submit a supplemental new drug application to the FDA in Q4 2019, with the aim of launching Epidiolex for TSC in 2020.